@article{6d7e0cc252254a5a9bc78bca36242e7e,
title = "Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders",
abstract = "The myeloproliferative disorders polycythaemia vera (PV), essential thombocythaemia (ET), and primary myelofibrosis (PMF) are clonal disorders of multipotent haematopoietic progenitors. The genetic cause of these diseases was not known until 2005, when several independent groups demonstrated that most patients with PV, ET and PMF acquire a single point mutation in the cytoplasmic tyrosine kinase JAK2 (JAK2V617F). These discoveries have changed the landscape for diagnosis and classification of PV, ET and PMF, and show the ability of genomic technologies to identify new molecular targets in human malignancies with pathogenetic, diagnostic and therapeutic significance.",
author = "Levine, {Ross L.} and Animesh Pardanani and Ayalew Tefferi and Gilliland, {D. Gary}",
note = "Funding Information: The Gililand Laboratory is supported by the US National Institutes of Health, the Howard Hughes Medical institute, the Leukemia and Lymphoma Society, and the Doris Duke Charitable Foundation. The Gilliland and Tefferi Laboratories are supported in part by a grant from the Myeloproliferative Disorders Foundation. D.G.G. is an Investigator of the Howard Hughes Medical Institute, and a Doris Duke Charitable Foundation Distinguished Clinical Scientist Award recipient. R.L.L. is an American Society of Hematology Basic Research Fellow Award recipient, and a Doris Duke Charitable Foundation Clinical Scientist Development Award recipient.",
year = "2007",
month = sep,
doi = "10.1038/nrc2210",
language = "English (US)",
volume = "7",
pages = "673--683",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "9",
}